Dedicated to NPs, PAs and rheumatologists who diagnose and treat arthritis and other musculoskeletal conditions.
Search:

key topics



navigation

Biologics And Rheumatoid Arthritis

The introduction of biologic agents into clinical practice has had a profound effect on the current management of rheumatoid arthritis (RA). These agents can rapidly enhance functional status and inhibit the progression of joint damage from the disease. Current biologic agents include abatacept, rituximab, adalimumab, etanercept, infliximab and anakinra.
Point/Counterpoint: Should You Prescribe Steroids For Rheumatoid Arthritis?
Yes, Dr. Deane says many studies have pointed to the positive results of treating rheumatoid arthritis (RA) with glucocorticoids. No, Dr. Goldman says corticosteroids have a significantly reduced role in the treatment of RA.


Emerging Agents For RA: Can They Have An Impact?
Given the recent advances in the understanding of rheumatoid arthritis, these authors offer a closer look at the pathogenesis of the disease and the potential impact of biologic therapies.


Biologics For Psoriatic Arthritis: Can They Have An Impact?
Reviewing the challenges of detecting and managing psoriatic arthritis, this author offers key insights on the differential diagnosis of the disease. Drawing upon his clinical experience and a couple of case studies, he also discusses the role of biologic response modifiers within the treatment armamentarium for this condition.


Biologic Therapy For RA: What You Should Know
In this month?s Q&A, the panelists explore biologic therapy in the treatment of rheumatoid arthritis (RA). Sharing their clinical experiences, they discuss key considerations for the use of these agents, the potential for patient resistance, how to gauge efficacy and monitor for potential side effects.


A Closer Look At Combination Therapy For RA
Given the debilitating effects of rheumatoid arthritis and recent changes in the evolution of RA treatment, these authors review the literature and discuss the potential impact of combination therapy for this disease.


Current Concepts In Detecting And Treating RA
In the debut of our ?Rheumatoid Arthritis? Q&A column, the expert panelists take a closer look at whether the blood test for rheumatoid factor (RF) can be beneficial in diagnosing rheumatoid arthritis (RA). They also discuss the evolution of methotrexate as a first-line treatment therapy. Without further delay, here is what the panelists had to say.


Pregabalin Gains FDA Approval For Fibromyalgia
The 100-patient study, which was recently published in the Journal of Rheumatology, found that 39 percent of patients studied achieved an ACR 20 response at 12 weeks after having subcutaneous injections of adalimumab 40 mg every other week. Revealing RA’s Impact On Sleep: What One Study ShowsBy Aaron Becker, Associate Editor A recent study published in Musculoskeletal Care determined that 35 percent of the rheumatoid arthritis (RA) patients enrolled experienced sleep disruption that ...


Secrets To Coding For RA And Osteoporosis Drugs
Secrets To Coding For RA And Osteoporosis Drugs Coding Corner: Secrets To Coding For RA And Osteoporosis Drugs - By Antanya A. Chung, CPC and Melesia R. Collins, CPC Rheumatoid arthritis (RA) usually requires a lifelong treatment regimen that may include medications, physical therapy, exercise, education and possibly surgery. Clinicians may prescribe disease-modifying antirheumatic drugs (DMARDs) after less potent drugs prove to be ineffective for a patient. Other DMARDs Clinicians May ...


RA Study: Etanercept Shows Sustained Efficacy For Up To Nine Years
In assessing 77 patients with early RA and 280 patients with longstanding RA who completed eight years of treatment with etanercept, researchers found that 75 percent of patients with early RA and 76 percent of those with longstanding RA achieved an ACR 20 score. A.L. Study Says: Abatacept Offers Sustained Benefits In RA Patients After two years of receiving treatment with abatacept, patients with RA maintained significant improvements, according to study findings that were presented ...


Assessing Older DMARDs And The Roles Of Diet In Treating RA
In this column, our panelists discuss the possible use of older disease-modifying antirheumatic drugs (DMARDs) in managing rheumatoid arthritis (RA), whether nutrition can have an impact in these patients, and the role of magnetic resonance imaging (MRI) in diagnosing RA and monitoring patient progress. Without further delay, here is what our panelists had to say.






© 2007 HMP Communications | All Rights Reserved
83 General Warren Blvd | Suite 100 | Malvern, PA 19355
Contact Us | Reprints/Permissions


July 19, 2008

Emerging Concepts In Treating Rheumatoid Arthritis

A complimentary CME Webcast Event

To register for this Web Archive program, click on Complimentary CME Webcast Event


This activity is for nurse practitioners, physician assistants, rheumatologists and internal medicine physicians who treat patients with rheumatoid arthritis (RA).


Panelists/Lectures

"What You Should Know About Treating Early RA"
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, Md.

"A Closer Look At The Efficacy And Safety Of Combination Therapy With Anti-TNF Agents"
Philip Mease, MD
Clinical Professor
University of Washington
School of Medicine
Chief, Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle

"What The Studies Reveal About Emerging Therapies For RA"
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas,Tx.

This activity is supported by an educational grant from Genentech and Biogen Idec. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).


Current Insights On Combination Therapy For Rheumatoid Arthritis

A complimentary CME Webcast Event
ON DEMAND
(Q&A with panelists to follow lectures)

To register for this Webcast program, click on Complimentary CME Webcast


This activity is geared to physicians, rheumatologists, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.

Agenda And Faculty

“Treating RA: The Shift To A More Aggressive Therapeutic Approach”
Linda Davis, MHS, PA-C
Assistant Professor
University Of North Texas Health Science Center

“What The Literature Reveals About Combination Therapy”
Kevin M. Latinis, MD, PhD
Division of Allergy, Clinical Immunology and Rheumatology
University of Kansas Medical Center

“New Biologic DMARDs: Can They Have An Impact?”
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas, Texas

This activity is supported by an educational grant from Bristol-Myers Squibb. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).


A Guide To Viscosupplementation For Osteoarthritis Knee Pain

A complimentary CME Web Archive Event

To register for this Web Archive program, click on Complimentary CME Web Archive Event


This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat osteoarthritis.

Agenda And Faculty

“A Closer Look At The Role Of Intraarticular Injections”
Frank Caruso, PA-C
Physician Assistant
Wake Forest University Baptist Medical Center
Winston-Salem, NC

“What The Literature Reveals About Viscosupplementation”
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, MD

“Mastering The Technique Of Intraarticular Injections”
Mike Rudzinski, PA-C
Physician Assistant
Buffalo Veterans Affairs Medical Center
Buffalo, NY

This activity is supported by an educational grant from Genzyme.
The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).



A Complimentary CME Webcast Event

A Guide To Infusion Therapy For Patients With Rheumatoid Arthritis

A Complimentary, On-Demand CME Webcast

To register for this Webcast program, click on Complimentary CME Webcast Event


This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.

AGENDA and FACULTY

"Reviewing The Role of DMARDs In Treating RA"
Don Flinn, PA-C
Physician Assistant, McBride Clinic, Oklahoma City, Ok.
Vice-President, Society Of Physician Assistants In Rheumatology

"Assessing The Potential of Biologic Therapies"
Mark Genovese, MD
Associate Professor of Medicine
Division of Immunology And Rheumatology
Stanford University School Of Medicine

"What You Should Know About Infusion Therapy"
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, Md.

This activity is supported by an educational grant from Bristol-Myers Squibb.

The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).